Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
|
|
NRX Pharmaceuticals, Inc. (NRXP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/07/2023 |
8-K/A
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"COMMON STOCK PURCHASE WARRANT NRX Pharmaceuticals, Inc. Warrant Shares: _______ Initial Exercise Date: December 6, 2023 Issue Date: June 6, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ______, 2023 1 and on or prior to 5:00 p.m. on ____, 2028 2 but not thereafter, to subscribe for and purchase from NRX Pharmaceuticals, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .          ...",
"Holder of the Preferred Investment Options to Purchase Common Stock",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of June 6, 2023, between NRX Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares, the Prefunded Warrants and Prefunded Warrant Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Common Warrants and the Common Warrant Shares, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of th...",
"LOCK-UP AGREEMENT",
"NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering" |
|
| 01/11/2021 |
8-K/A
| Quarterly results |
|
|